Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRE + Nivolumab in Metastatic Pancreatic Cancer
NCT04212026Phase 2Terminated
- Sponsor
- University Hospital Basel
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by University Hospital Basel. Started Jun 2020; status: terminated.
02
Drugs
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04212026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212026.